DE60210488T2 - Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten - Google Patents
Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten Download PDFInfo
- Publication number
- DE60210488T2 DE60210488T2 DE60210488T DE60210488T DE60210488T2 DE 60210488 T2 DE60210488 T2 DE 60210488T2 DE 60210488 T DE60210488 T DE 60210488T DE 60210488 T DE60210488 T DE 60210488T DE 60210488 T2 DE60210488 T2 DE 60210488T2
- Authority
- DE
- Germany
- Prior art keywords
- acid
- proteins
- hydroxyoleic
- hydroxyoleic acid
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 239000002253 acid Substances 0.000 title description 12
- JBSOOFITVPOOSY-KTKRTIGZSA-N 2-hydroxyoleic acid Chemical compound CCCCCCCC\C=C/CCCCCCC(O)C(O)=O JBSOOFITVPOOSY-KTKRTIGZSA-N 0.000 claims abstract description 82
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 206010020772 Hypertension Diseases 0.000 claims abstract description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 208000008589 Obesity Diseases 0.000 claims abstract description 6
- 235000020824 obesity Nutrition 0.000 claims abstract description 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 17
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 11
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 11
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 11
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000005642 Oleic acid Substances 0.000 claims description 11
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 11
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 9
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 8
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims description 5
- JUUBMADBGZQVFT-KHPPLWFESA-N (z)-2-methyloctadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCC(C)C(O)=O JUUBMADBGZQVFT-KHPPLWFESA-N 0.000 claims description 5
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims description 5
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 claims description 3
- 235000021322 Vaccenic acid Nutrition 0.000 claims 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 42
- 108091006027 G proteins Proteins 0.000 abstract description 39
- 102000030782 GTP binding Human genes 0.000 abstract description 39
- 108091000058 GTP-Binding Proteins 0.000 abstract description 39
- 230000033228 biological regulation Effects 0.000 abstract description 9
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000004075 alteration Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 28
- 230000037396 body weight Effects 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 17
- 229930195729 fatty acid Natural products 0.000 description 17
- 239000000194 fatty acid Substances 0.000 description 17
- 150000004665 fatty acids Chemical class 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 230000001631 hypertensive effect Effects 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- 235000021313 oleic acid Nutrition 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 7
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- -1 polyoxyethylene Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 101150073031 cdk2 gene Proteins 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000030570 cellular localization Effects 0.000 description 3
- UWHZIFQPPBDJPM-FPLPWBNLSA-N cis-vaccenic acid Chemical compound CCCCCC\C=C/CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-FPLPWBNLSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000005555 hypertensive agent Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000004873 systolic arterial blood pressure Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DJCQJZKZUCHHAL-UHFFFAOYSA-N (Z)-9-Pentadecensaeure Natural products CCCCCC=CCCCCCCCC(O)=O DJCQJZKZUCHHAL-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 2
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 2
- 102000002427 Cyclin B Human genes 0.000 description 2
- 108010068150 Cyclin B Proteins 0.000 description 2
- 102000006313 Cyclin D3 Human genes 0.000 description 2
- 108010058545 Cyclin D3 Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 231100000762 chronic effect Toxicity 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000192036 Psychrobacter urativorans Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- MWRBNPKJOOWZPW-XPWSMXQVSA-N [3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C\CCCCCCCC MWRBNPKJOOWZPW-XPWSMXQVSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical class C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- LKOVPWSSZFDYPG-WUKNDPDISA-N trans-octadec-2-enoic acid Chemical compound CCCCCCCCCCCCCCC\C=C\C(O)=O LKOVPWSSZFDYPG-WUKNDPDISA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200102269 | 2001-10-11 | ||
| ES200102269A ES2186576B1 (es) | 2001-10-11 | 2001-10-11 | Acido 2-hidroxioleico para utilizar como medicamento. |
| PCT/ES2002/000475 WO2003030891A1 (es) | 2001-10-11 | 2002-10-09 | Utilizacion del acido hidroxioleico y compuestos analogos del mismo en la fabricacion de medicamentos |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60210488D1 DE60210488D1 (de) | 2006-05-18 |
| DE60210488T2 true DE60210488T2 (de) | 2006-12-14 |
Family
ID=8499164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60210488T Expired - Lifetime DE60210488T2 (de) | 2001-10-11 | 2002-10-09 | Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20050014831A1 (enExample) |
| EP (1) | EP1435235B1 (enExample) |
| JP (1) | JP4737931B2 (enExample) |
| CN (3) | CN101259122B (enExample) |
| AT (1) | ATE322261T1 (enExample) |
| BR (1) | BRPI0213165B8 (enExample) |
| CA (1) | CA2463348C (enExample) |
| DE (1) | DE60210488T2 (enExample) |
| ES (2) | ES2186576B1 (enExample) |
| MX (1) | MXPA04003255A (enExample) |
| PT (1) | PT1435235E (enExample) |
| RU (1) | RU2310445C2 (enExample) |
| WO (1) | WO2003030891A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2229935B1 (es) * | 2003-10-10 | 2006-10-01 | Universitat De Les Illes Balears | Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales. |
| JP2009051732A (ja) * | 2005-12-13 | 2009-03-12 | Meiji Seika Kaisha Ltd | Ｐｐａｒリガンド活性を有する組成物 |
| CN101570481B (zh) * | 2008-04-30 | 2012-02-01 | 上海医药工业研究院 | 一种多羟基长链脂肪酸及其分离提取方法和在抑制芳香化酶活性中的应用 |
| ES2342997B1 (es) * | 2008-12-09 | 2011-06-06 | Universitat De Les Illes Balears | Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento. |
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| WO2011089265A1 (en) | 2010-01-25 | 2011-07-28 | Bridge Bioresearch Plc | Use of fatty acid compounds for lowering blood glucose levels |
| CN101985420B (zh) * | 2010-01-29 | 2014-04-30 | 苏州润新生物科技有限公司 | 油酸酯及其制备方法和在制备用于治疗高血压及其并发症的药物中的应用 |
| ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
| WO2013108428A1 (ja) * | 2012-01-19 | 2013-07-25 | 日本水産株式会社 | 食欲抑制剤 |
| WO2013132092A1 (en) | 2012-03-09 | 2013-09-12 | Pensieve International Plc | Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat |
| ES2734554T3 (es) * | 2012-09-26 | 2019-12-10 | Tangent Reprofiling Ltd | Combinación de benzo(iso)oxazolpiperidinas con ácido linoleico conjugado |
| GB201217296D0 (en) | 2012-09-27 | 2012-11-14 | Alta Innovations Ltd | Method of treatment and/or prevention |
| WO2016062746A1 (en) | 2014-10-21 | 2016-04-28 | Universitat De Les Illes Balears | Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases |
| US10756968B2 (en) | 2015-01-26 | 2020-08-25 | Rapid7, Inc. | Network resource management devices methods and systems |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61297A (ja) * | 1984-06-12 | 1986-01-06 | 日本油脂株式会社 | オレイン酸の製造法 |
| GB8603621D0 (en) * | 1986-02-14 | 1986-03-19 | Habib N | Modifying lipid structure of cell membranes |
| JPS6344843A (ja) * | 1986-08-13 | 1988-02-25 | Kao Corp | 油中水中油型乳化油脂組成物 |
| CN1035925C (zh) * | 1988-11-16 | 1997-09-24 | 许正 | 亲细胞非均质分子脂质的制备方法 |
| US5422371A (en) * | 1992-05-27 | 1995-06-06 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| CN1118228A (zh) * | 1995-03-16 | 1996-03-13 | 姜训书 | 松籽果酱 |
| CN1118218A (zh) * | 1995-03-16 | 1996-03-13 | 姜训书 | 松籽油的制作方法及松籽保健食用油 |
| GB9506837D0 (en) * | 1995-04-03 | 1995-05-24 | Scotia Holdings Plc | Triglycerides |
| PT771817E (pt) * | 1995-10-30 | 2003-06-30 | Oleoyl Estrone Developments S | Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso |
| US5856537A (en) * | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| DE19727636C1 (de) * | 1997-06-28 | 1998-11-19 | Rwe Dea Ag | Verfahren zur Herstellung von 2-Alkylcarbonsäuren |
| CN1212867A (zh) * | 1997-09-29 | 1999-04-07 | 宋凤亭 | 防治心脑血管疾病的组合物 |
| DK0948963T3 (da) * | 1998-01-21 | 2003-08-11 | Fideline | Pacificerende pheromoner til grise med henblik på nedsættelse af stress, angst og aggressivitet |
| US6214875B1 (en) * | 1998-04-14 | 2001-04-10 | Zhenhua Yang | Anticancer effects of specific branched-chain fatty acids and related production process |
| WO1999058120A1 (en) * | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| WO2002051406A1 (en) * | 2000-12-23 | 2002-07-04 | Creighton University | Methods for inducing apoptosis and inhibiting proliferation in cancer cells |
| DE10130491A1 (de) * | 2001-06-25 | 2003-04-17 | Heirler Horst | Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas |
-
2001
- 2001-10-11 ES ES200102269A patent/ES2186576B1/es not_active Expired - Fee Related
-
2002
- 2002-10-09 AT AT02783094T patent/ATE322261T1/de active
- 2002-10-09 CN CN2008100917941A patent/CN101259122B/zh not_active Expired - Fee Related
- 2002-10-09 JP JP2003533923A patent/JP4737931B2/ja not_active Expired - Lifetime
- 2002-10-09 RU RU2004114229/15A patent/RU2310445C2/ru active
- 2002-10-09 EP EP02783094A patent/EP1435235B1/en not_active Expired - Lifetime
- 2002-10-09 DE DE60210488T patent/DE60210488T2/de not_active Expired - Lifetime
- 2002-10-09 CA CA2463348A patent/CA2463348C/en not_active Expired - Lifetime
- 2002-10-09 CN CNB028201132A patent/CN100471492C/zh not_active Expired - Lifetime
- 2002-10-09 PT PT02783094T patent/PT1435235E/pt unknown
- 2002-10-09 BR BRPI0213165A patent/BRPI0213165B8/pt not_active IP Right Cessation
- 2002-10-09 WO PCT/ES2002/000475 patent/WO2003030891A1/es not_active Ceased
- 2002-10-09 CN CN2008100917937A patent/CN101259121B/zh not_active Expired - Fee Related
- 2002-10-09 ES ES02783094T patent/ES2261752T3/es not_active Expired - Lifetime
- 2002-10-09 MX MXPA04003255A patent/MXPA04003255A/es active IP Right Grant
- 2002-10-09 US US10/488,726 patent/US20050014831A1/en not_active Abandoned
-
2008
- 2008-04-15 US US12/082,938 patent/US7851507B2/en not_active Expired - Lifetime
-
2010
- 2010-11-04 US US12/939,641 patent/US8778995B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BR0213165A (pt) | 2004-09-14 |
| US20110136906A1 (en) | 2011-06-09 |
| CA2463348C (en) | 2011-04-05 |
| US20050014831A1 (en) | 2005-01-20 |
| RU2310445C2 (ru) | 2007-11-20 |
| WO2003030891A1 (es) | 2003-04-17 |
| EP1435235B1 (en) | 2006-04-05 |
| US20090082446A1 (en) | 2009-03-26 |
| CN101259121B (zh) | 2011-04-06 |
| US8778995B2 (en) | 2014-07-15 |
| CN101259121A (zh) | 2008-09-10 |
| JP4737931B2 (ja) | 2011-08-03 |
| ES2186576B1 (es) | 2004-09-16 |
| ES2186576A1 (es) | 2003-05-01 |
| BRPI0213165B1 (pt) | 2018-01-23 |
| CN100471492C (zh) | 2009-03-25 |
| MXPA04003255A (es) | 2005-01-25 |
| CN101259122A (zh) | 2008-09-10 |
| CA2463348A1 (en) | 2003-04-17 |
| DE60210488D1 (de) | 2006-05-18 |
| CN101259122B (zh) | 2011-04-06 |
| PT1435235E (pt) | 2006-08-31 |
| US7851507B2 (en) | 2010-12-14 |
| JP2005527479A (ja) | 2005-09-15 |
| EP1435235A1 (en) | 2004-07-07 |
| BRPI0213165B8 (pt) | 2021-05-25 |
| ES2261752T3 (es) | 2006-11-16 |
| RU2004114229A (ru) | 2005-04-20 |
| CN1688302A (zh) | 2005-10-26 |
| ATE322261T1 (de) | 2006-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8778995B2 (en) | Use of hydroxyoleic acid and related compounds in the manufacture of drugs | |
| DE3779500T2 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
| DE69635959T2 (de) | Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme | |
| DE69533940T2 (de) | Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren | |
| DE3789576T2 (de) | Verwendung von Inositol-Triphosphat zur Behandlung von Metallvergiftung. | |
| DE3486235T2 (de) | Fettsäure-Zusammensetzungen. | |
| DE69730330T2 (de) | Verwendung von l-acetylcarnitin, l-isovalerylcarnitin oder l-propionyl-carnitin zur steigerung des igf-spiegels | |
| DE60130023T2 (de) | Behandlung der nebenwirkungen von statinen | |
| DE69814834T2 (de) | Ernährungszusammensetzung zur verbesserung der zellenenergie | |
| DE60118019T2 (de) | Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung | |
| DE69612755T2 (de) | Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen | |
| EP0607231A1 (de) | Verwendung einer emulsion, zur herstellung eines arzneimittels zur i.v.-verabreichung zur behandlung von hauterkrankungen. | |
| DE19528461A1 (de) | Präparat zur Ernährung | |
| DE3115080C2 (de) | Arzneimittel enthaltend Cytidindiphosphocholin und Lecithin | |
| DE60224299T2 (de) | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor | |
| EP2731454A1 (de) | Diätisches mehrkomponentensystem | |
| DE60316362T2 (de) | Verwendung von hydroxyölsäure und verwandten verbindungen als funktionelle nahrungsmittelzusatzstoffe | |
| EP1064002B1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| DE69023939T2 (de) | Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten. | |
| DE60207442T2 (de) | VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION | |
| DE60124516T3 (de) | Kombination des lezithins mit ascorbinsäure | |
| DE69802512T2 (de) | Feste zusammensetzungen für orale verabreichung die alkanoyl-l-carnitin-magnesium-tartrat enthalten | |
| DE69533742T2 (de) | Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
| DE60213237T2 (de) | Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |